ME Stock Overview Operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
23andMe Holding Co. Competitors Price History & Performance
Summary of share price highs, lows and changes for 23andMe Holding Historical stock prices Current Share Price US$3.27 52 Week High US$19.34 52 Week Low US$2.66 Beta 1.16 1 Month Change 5.14% 3 Month Change -51.76% 1 Year Change -81.46% 3 Year Change -97.80% 5 Year Change n/a Change since IPO -98.33%
Recent News & Updates 23andMe Holding Co. Announces Reduce Overall Headcount Nov 12
23andMe Holding Co. to Report Q2, 2025 Results on Nov 12, 2024 Nov 07
23andMe Holding Regains Compliance with Nasdaq Minimum Bid Price Requirement and Corporate Governance Requirements Oct 31
23andMe Holding Co. Announces Board Appointments Oct 29
23andMe Holding Co. Receives A Deficiency Letter Regarding Nasdaq Listing Rule 5605 Sep 19
23andMe Holding Co. Announces Board Resignations Sep 18 See more updates 23andMe Holding Co. Announces Reduce Overall Headcount Nov 12
23andMe Holding Co. to Report Q2, 2025 Results on Nov 12, 2024 Nov 07
23andMe Holding Regains Compliance with Nasdaq Minimum Bid Price Requirement and Corporate Governance Requirements Oct 31
23andMe Holding Co. Announces Board Appointments Oct 29
23andMe Holding Co. Receives A Deficiency Letter Regarding Nasdaq Listing Rule 5605 Sep 19
23andMe Holding Co. Announces Board Resignations Sep 18 23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechism ULBP6-Targeting Antibody Currently in a Phase 1 Trial Anne Wojcicki delivered a non-binding indication of interest to acquire remaining 99.7% stake in 23andMe Holding Co. (NasdaqCM:ME) for approximately $190 million. Aug 01
23andMe Holding Co. to Report Q1, 2025 Results on Aug 08, 2024 Jul 26
23andMe Holding Co., Annual General Meeting, Aug 28, 2024 Jun 29
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, Targeting CD200R1, at the 2024 ASCO Annual Meeting Jun 05
23andMe Holding Co. Reports Unaudited Consolidated Goodwill Impairment for the Fourth Quarter Ended March 31, 2024 May 25
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 24
23andMe Holding Co. to Report Q4, 2024 Results on May 23, 2024 May 12
The Nasdaq Stock Market LLC Grants 23andMe Holding an Additional 180 Days, or Until November 4, 2024, to Regain Compliance with the Minimum Bid Price Requirement Under Nasdaq Marketplace Rule 5550(a)(2) May 11
23andMe Holding Co. to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology Annual Meeting Apr 26
New major risk - Share price stability Apr 19
Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation Apr 16
23andMe Holding Co. Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 Mar 20
Insider notifies of intention to sell stock Mar 11
Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26% Mar 02 23andMe Holding Co. Reports Goodwill Impairment for the Third Quarter Ended December 31, 2023
23andMe Holding Co. Announces U.S. Food and Drug Administration Clears Investigational New Drug Application for 23ME-01473 Feb 01
23andMe Holding Co. to Report Q3, 2024 Results on Feb 07, 2024 Jan 25
23andMe Holding Co. Provides Update on Class Action Dec 22
23andMe Holding Co. Provides Update on Class Action Dec 21
23andMe Holding Co. Announces Further Expansion of 23ME-00610 Phase 1/2a Clinical Trial in Advanced Neuroendocrine and Ovarian Cancer Patient Cohorts Dec 19
Insider notifies of intention to sell stock Dec 06
23andMe Holding Receives Deficiency Letter from Nasdaq Regarding Non-Compliance Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5450(a)(1) Nov 15
23andMe Holding Receives Deficiency Letter from Nasdaq Regarding Non-Compliance Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5450(a)(1) Nov 14
23Andme Holding Co. Reaffirms Earnings Guidance for the Year 2024 Nov 10
Price target decreased by 20% to US$3.58 Nov 10
High number of new and inexperienced directors Nov 09
23andMe Holding Co. Announces Updated Safety and Preliminary Efficacy Data from the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 Nov 07
23andMe Holding Co. to Report Q2, 2024 Results on Nov 08, 2023 Oct 26
23Andme Holding Co. Grants New FDA Clearance to Report Additional BRCA Variants Sep 01 23andMe Holding Co. Revises Earnings Guidance for the Year Ending March 31, 2024
Insider notifies of intention to sell stock Jul 30
23andMe Holding Co., Annual General Meeting, Sep 06, 2023 Jul 28
23andMe Holding Co. to Report Q1, 2024 Results on Aug 08, 2023 Jul 26
We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate Jul 13
Insider notifies of intention to sell stock Jul 03
23andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected Jun 15
Price target decreased by 12% to US$4.50 Jun 15
Price target decreased by 9.9% to US$5.13 May 31
23andMe Holding Co. Provides Earnings Guidance for the Full Year Fiscal 2024 May 27
Full year 2023 earnings: EPS exceeds analyst expectations May 27
23andMe Holding Co. to Report Q4, 2023 Results on May 25, 2023 May 12
23Andme Holding Co. Announces the Appointment of Reza Afkhami as Chief Corporate Development Officer May 09
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Feb 09
23andMe Holding Co. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2023 Feb 09
23andMe Holding Co. to Report Q3, 2023 Results on Feb 08, 2023 Jan 27
Insider notifies of intention to sell stock Dec 09
Director recently sold US$60k worth of stock Nov 16
High number of new and inexperienced directors Nov 16
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 08 23andMe Holding Co. Reconfirms Earnings Guidance for the Full Year Ending March 31, 2023
23anMe Granted New FDA Clearance to Provide Interpretive Drug Information for A Commonly Prescribed Cholesterol Medication Oct 28
23andMe Holding Co. to Report Q2, 2023 Results on Nov 07, 2022 Oct 25
23andMe: Disappointing Results Could Mean Potential Acquisition Target Sep 27
Daniel Chu Joins 23andMe Holding Co. as Chief Product Officer Sep 20
23andMe: Treacherous Path To Profitability Aug 26
23andMe Holding Co. Announces CFO Changes Aug 20
23andMe drops 8% as CFO resigns Aug 19
23andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target Aug 11
23andMe Holding Co. Provides Earnings Guidance for 2023 Aug 09
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
23andMe Q1 2023 Earnings Preview Aug 07
23andMe Holding Co. to Report Q1, 2023 Results on Aug 08, 2022 Jul 26
23andMe: Holiday Miracles Not Enough, Growth Path Too Expensive Jun 15
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 27
23andMe Holding Co. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023 May 27
23andMe Holding Co. to Report Q4, 2022 Results on May 26, 2022 May 13
Price target decreased to US$8.50 Apr 27
High number of new and inexperienced directors Apr 27
23andMe Holding Co., Annual General Meeting, Aug 25, 2022 Apr 16
Director recently bought US$51k worth of stock Mar 13
23andMe: A Genetics Innovator Positioned For Growth Feb 19
Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues Feb 18
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Feb 12
23Andme Holding Co. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2022 Feb 11
23andMe Holding Co. to Report Q3, 2022 Results on Feb 10, 2022 Jan 28
23andMe Holding Co. Receives FDA Clearance for Direct-To-Consumer Genetic Test on A Hereditary Prostate Cancer Marker Jan 12
23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors Jan 07
23andMe: No Surprises With Recent Earnings, But Long-Term Story Remains Positive Nov 21
Second quarter 2022 earnings released: US$0.041 loss per share (vs US$1.36 loss in 2Q 2021) Nov 13
23andMe Stock: Continued Drug-Development Progress Can Deliver Long-Term Gains Oct 03 Shareholder Returns ME US Healthcare US Market 7D -2.4% -4.1% -2.4% 1Y -81.5% -10.2% 23.4%
See full shareholder returns
Return vs Market: ME underperformed the US Market which returned 23.3% over the past year.
Price Volatility Is ME's price volatile compared to industry and market? ME volatility ME Average Weekly Movement 15.9% Healthcare Industry Average Movement 7.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ME's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ME's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company 23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
Show more 23andMe Holding Co. Fundamentals Summary How do 23andMe Holding's earnings and revenue compare to its market cap? ME fundamental statistics Market cap US$84.49m Earnings (TTM ) -US$615.31m Revenue (TTM ) US$193.26m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ME income statement (TTM ) Revenue US$193.26m Cost of Revenue US$103.37m Gross Profit US$89.89m Other Expenses US$705.20m Earnings -US$615.31m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -23.82 Gross Margin 46.51% Net Profit Margin -318.39% Debt/Equity Ratio 0%
How did ME perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 10:15 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources 23andMe Holding Co. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Gaurav Goparaju Berenberg Daniel Grosslight Citigroup Inc Poon Mah TD Cowen
Show 0 more analysts 
